373 Treatments for acute decompensated heart failure have significant international variations: an analysis of the randomized interventions with tezosentan (RITZ-1) trial

Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers

“…A large-scale trial prospective randomized trial of nesiritide in the treatment of AHF is currently planned to test safety and efficacy. Endothelin antagonists have been studied in the treatment of AHF, but a large randomized trial of tezosentan 1 mg/h versus placebo in 1400 AHF patients with dyspnea was stopped for futility without significant safety concerns (174)(175)(176)(177)(178).…”